STIM
Neuronetics, Inc. NASDAQ$2.02
Mkt Cap $140.6M
52w Low $0.80
30.1% of range
52w High $4.85
50d MA $1.45
200d MA $2.27
P/E (TTM)
-3.4x
EV/EBITDA
-5.3x
P/B
5.1x
Debt/Equity
4.0x
ROE
-174.3%
P/FCF
-4.3x
RSI (14)
—
ATR (14)
—
Beta
0.87
50d MA
$1.45
200d MA
$2.27
Avg Volume
2.3M
About
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses tran…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | BMO | -0.12 | -0.10 | +16.7% | 1.23 | -2.4% | +9.8% | +9.8% | +23.6% | +17.9% | +30.1% | — |
| Nov 4, 2025 | BMO | -0.12 | -0.13 | -8.3% | 2.87 | -0.3% | -4.5% | -4.5% | -12.2% | -20.6% | -25.4% | — |
| Aug 5, 2025 | BMO | -0.08 | -0.15 | -87.5% | 4.55 | +0.0% | -6.6% | -6.6% | -11.9% | -9.2% | -13.8% | — |
| May 6, 2025 | BMO | -0.13 | -0.21 | -61.5% | 4.50 | +0.0% | +1.3% | +1.3% | +3.3% | -1.6% | -8.0% | — |
| Mar 4, 2025 | BMO | -0.26 | -0.33 | -26.9% | 5.06 | +8.1% | +7.1% | +7.1% | -2.0% | +0.2% | -14.4% | — |
| Nov 12, 2024 | BMO | -0.23 | -0.29 | -26.1% | 0.69 | +0.0% | -11.7% | -11.7% | +14.5% | +2.9% | +13.2% | — |
| Aug 12, 2024 | BMO | -0.27 | -0.33 | -22.2% | 0.74 | +2.0% | -0.8% | -0.8% | +11.4% | +29.6% | +50.3% | — |
| May 7, 2024 | BMO | -0.33 | -0.27 | +18.2% | 2.60 | +0.8% | -1.9% | -1.9% | -4.2% | -3.5% | -1.5% | — |
| Mar 5, 2024 | BMO | -0.26 | -0.19 | +26.9% | 3.22 | +3.7% | +24.8% | +24.8% | +23.3% | +28.0% | +31.4% | — |
| Nov 7, 2023 | BMO | -0.30 | -0.33 | -10.0% | 1.40 | +0.7% | +4.3% | +4.3% | -7.5% | -9.3% | -10.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.35 | $1.31 | -3.0% | +12.6% | +7.4% | +18.5% | +8.1% | +3.7% |
| Aug 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.55 | $4.55 | +0.0% | -6.6% | -11.9% | -9.2% | -13.8% | -15.2% |
| Mar 5 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $5.06 | $5.47 | +8.1% | +7.1% | -2.0% | +0.2% | -14.4% | -10.3% |
| Mar 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.06 | $5.47 | +8.1% | +7.1% | -2.0% | +0.2% | -14.4% | -10.3% |
| Aug 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.74 | $0.75 | +1.0% | +12.3% | +30.7% | +51.6% | +36.7% | +38.1% |
| Aug 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $0.74 | $0.76 | +2.0% | -0.8% | +11.4% | +29.6% | +50.3% | +35.6% |
| Aug 12 | William Blair | Downgrade | Outperform → Market Perform | — | $1.78 | $1.25 | -29.8% | -58.1% | -58.5% | -53.4% | -45.8% | -37.1% |
| May 14 | William Blair | Upgrade | Market Perform → Outperform | — | $2.56 | $2.64 | +3.1% | -6.6% | -5.1% | -1.6% | +2.0% | -1.2% |
| Mar 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.22 | $3.34 | +3.7% | +24.8% | +23.3% | +28.0% | +31.4% | +33.9% |
| May 10 | JMP Securities | Maintains | Market Outperform → Outperform | — | $2.80 | $2.84 | +1.4% | +0.4% | -1.8% | -0.7% | +0.7% | -3.6% |
Recent Filings
8-K · 2.02
!! High
Neuronetics, Inc. -- 8-K 2.02: Earnings Results
Neuronetics (STIM) disclosed quarterly earnings results via SEC filing, with full details available in the attached press release exhibit for investor review.
May 5
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
STIM's CFO transition amid reaffirmed guidance suggests management stability concerns, warranting investor scrutiny on whether leadership changes signal operational challenges or strategic repositioning affecting near-term performance.
Apr 6
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
The company disclosed investor presentation materials on March 17, 2026, suggesting upcoming investor meetings or conferences that could signal strategic updates or capital plans worth monitoring.
Mar 17
8-K
Neuronetics, Inc. -- 8-K Filing
Neuronetics secured a voting agreement with Madryn Parties committing their shares to support Board recommendations at the 2026 annual meeting, strengthening management's control over key proposals.
Mar 2
8-K
Neuronetics, Inc. -- 8-K Filing
I cannot provide a meaningful analysis from this filing summary as it contains only technical SEC metadata and reference information without substantive business developments or outcomes relevant to investor decision-making.
Feb 25
8-K
Neuronetics, Inc. -- 8-K Filing
Neuronetics (STIM) issued forward-looking statements in its 8-K filing regarding future operations and financial performance, which carry inherent risks and uncertainties subject to safe harbor protections under U.S. and Canadian securities laws.
Feb 10
Data updated apr 27, 2026 3:12am
· Source: massive.com